Hematology

Tessa Therapeutics presented positive data from the phase 2 CHARIOT study of TT11 in December 2021.

The oncologist from Children's Hospital of Philadelphia discussed long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.

Review top news and interview highlights from the week ending August 12, 2022.

Nula-cel is intended to directly correct the mutation that causes sickle cell disease.

The FDA recently accepted the company’s BLA for omidubicel for priority review.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A recent comparison of health-related quality of life scores also favored ide-cel over belantamab mafodotin treatment.

Marker will initiate a company-sponsored study after an initial trial at Baylor College of Medicine showed positive safety data.

Experts discuss providing supportive care to patients receiving CAR T-cell therapy.

CT103A, a fully human BCMA-directed CAR T-cell therapy, demonstrated deepening efficacy with an acceptable toxicity profile, according to updated data from the phase 1/2 FUMANBA-1 trial.

Among the programs involved are therapies for multiple myeloma and B-cell malignancies.

Pre-clinical data showed that EZ-T cells have increased anti-tumor activity compared with traditional iPSC-derived T-cells.

The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed work that needs to be done to support the use of CAR T therapy.

Review top news and interview highlights from the week ending August 5, 2022.

Topline results are expected to be announced by the fourth quarter of 2022.

Incidences of graft versus host disease will be a focal point of the study.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

UCART2022 is an allogeneic therapy that targets both CD20 and CD22.

Omidubicel demonstrated neutrophil engraftment a median of 10 days faster than standard UCBT.

Milan Zdravkovic, MD, PhD, chief medical officer of SNIPR Biome, discussed the company’s ongoing research on targeting E Coli in the blood with CRISPR-based medication.

Experts shared opinions about the future of gene therapy in sickle cell and other rare diseases.

Review top news and interview highlights from the week ending July 29, 2022.

The associate professor at Fred Hutch Cancer Center discussed next steps with the clinical trial being conducted Fred Hutch Cancer Center.

The company announced successful neutrophil and platelet engraftment for the first patient dosed.

The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed new CAR T-cell therapies being investigated for hematologic malignancies.